PCV91 THE COST-EFFECTIVENESS OF ROSUVASTATIN VERSUS ATORVASTATIN FOR THE PREVENTION OF CARDIOVASCULAR MORBIDITY AND MORTALITY IN PATIENTS WITH HIGH BASELINE RISK-A SWEDISH ECONOMIC EVALUATION OF THE JUPITER TRIAL

Nov 1, 2010, 00:00
10.1016/S1098-3015(11)72433-0
https://www.valueinhealthjournal.com/article/S1098-3015(11)72433-0/fulltext
Title : PCV91 THE COST-EFFECTIVENESS OF ROSUVASTATIN VERSUS ATORVASTATIN FOR THE PREVENTION OF CARDIOVASCULAR MORBIDITY AND MORTALITY IN PATIENTS WITH HIGH BASELINE RISK-A SWEDISH ECONOMIC EVALUATION OF THE JUPITER TRIAL
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)72433-0&doi=10.1016/S1098-3015(11)72433-0
First page : A358
Section Title : RESEARCH POSTER ABSTRACTS
Open access? : No
Section Order : 592
Categories :
Tags :
Regions :
ViH Article Tags :